India removes cap from patented rare disease drugs
07-01-2019
fabioberti / Shutterstock.com
The lobby group for India’s pharma industry has asked the US Trade Representative (USTR) office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Trade Representative, Indian Pharmaceutical Alliance, Indian Patent Office, priority watch list, patents, trademarks, compulsory licensing
